Dendritic-cell vaccine (DCVAC) with first-line chemotherapy in patients with stage IV NSCLC: Final analysis of phase II, open label, randomized, multicenter trial.
/in Dendritic Cells, NSCLC /von 2019-06-02 / J Clin Oncol 37, 2019 (suppl; abstr 9039)Neoantigen-based personalized DC vaccine for lung cancer: An update of translational study.
/in Dendritic Cells, NSCLC /von 2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e20674)Radiofrequency deep hyperthermia combined with chemotherapy in the treatment of advanced non-small cell lung cancer
/in Hyperthermia, International Publications, NSCLC /von 2019-04-20 / Chin. Med. J. 2019 Apr;132(8):922-927[Vaccines for the treatment of non-small cell lung cancer]
/in Dendritic Cells, International Publications, NSCLC /von 2019-03-20 / Rev Mal Respir 2019 Mar;36(3):415-425Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients‘ preference-based study (PPPS)
/in Dendritic Cells, International Publications, NSCLC /von 2018-10-29 / Clin Transl Oncol 2019 Jun;21(6):721-728Recombinant Newcastle disease virus expressing human IFN-λ1 (rL-hIFN-λ1)-induced apoptosis of A549 cells is connected to endoplasmic reticulum stress pathways
/in Dendritic Cells, International Publications, NSCLC /von 2018-09-23 / Thorac Cancer 2018 Nov;9(11):1437-1452Dendritic-cell vaccine (DCVAC) with first line chemotherapy in patients with stage IV NSCLC primary analysis of phase 2, open-label, randomized, multicenter trial.
/in Dendritic Cells, NSCLC /von 2018-06-03 / J Clin Oncol 36, 2018 (suppl; abstr 9051)Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC
/in Dendritic Cells, International Publications, NSCLC /von 2017-12-21 / BMC Cancer 2017 12;17(1):884Increased cycles of DC/CIK immunotherapy decreases frequency of Tregs in patients with resected NSCLC
/in Dendritic Cells, International Publications, NSCLC /von 2017-09-21 / Int. Immunopharmacol. 2017 Nov;52:197-202
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de